ClinicalTrials.gg
RecruitingNCT06524310Updated Nov 17, 2026

Effects of rTMS on Cognitive Functions and Behavior in Individuals With Autism Spectrum Disorder

An interventional study of Stimulation with low frequency rTMS at 1 Hz in Autism Spectrum Disorder, sponsored by King Saud University. Recruiting at 1 site in Saudi Arabia. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by King Saud University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.
Updated Nov 17, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
5 Years to 11 Years
Sex
All
01

Study summary

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with core symptoms that include impairments in social communication and restricted and repetitive behaviors, interests, and activities. Social cognition is a broad term used to understand, perceive, and interpret information about others and ourselves in a social context. Impairments in social cognition are often highlighted as a potential mechanism underlying social disability in autism spectrum disorder. Repetitive transcranial magnetic stimulation is a noninvasive technique that modulates brain activity through targeted electromagnetic pulses. It's one of the methods used to deliver electrical stimuli through the scalp in conscious humans. Recently, rTMS has not only been used for the treatment of major depressive disorders, but it has also been advanced as a potential therapeutic technique to treat neurologic disorders such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis, and many other neuropsychiatric disorders. High-order cognitive functions, such as Executive function (EF) and social cognition, rely on neural network oscillations in the gamma frequency (30-80 Hz) band. It has been proposed that GABA-inhibitory interneurons in the dorsolateral prefrontal cortex (DLPFC) contribute to the synchronization of pyramidal neurons, which is necessary for EF performance. Additionally, given the theory of abnormal synaptic plasticity and excitation/inhibition ratio in ASD, as well as the ability of TMS to modify cortical excitability and plasticity, it leads to exploring the therapeutic potential of rTMS in ASD. This study examines the effectiveness of low-frequency rTMS in improving social, cognitive, and sensory function in individuals with ASD. Further understanding of the effect of low-frequency rTMS in altering the cognitive function in ASD individuals with ASD may help to achieve some answers related to the mechanism behind ASD.

Read the detailed description

Statement of the Problem:

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder. Core ASD symptoms include impairments in social communication and restricted and repetitive behaviors, interests, and activities. ASD may also present with secondary signs, including hyperactivity, self-injury, and co-occurrence of some psychiatric conditions, e.g., anxiety and major depression. The symptoms of ASD are persistent and typically appear during the first three years of life. It can be recognized and clinically evident in early childhood.

In most cases, but not all, ASD symptoms might follow a steady course without remission. However, deficits and impairment in social skills and behavioral patterns may not be noticed and diagnosed as symptoms of ASD until the child faces significant life demands such as social, educational, and occupational tasks. Moreover, this functional limitation may vary among persons with ASD and could develop over time.

In the past 50 years, ASD's description has changed from a rare disease of childhood-onset to a well-publicized, advocated, and researched lifelong condition, recognized as relatively common and very heterogeneous. Since the 1970s, several studies have reported increased ASD cases. The report documented that the male/female ratio is approximately 4 per 1. According to the Centers for Disease Control, the prevalence of ASD increased from 1 in 80 (1.25%) in 2011-2013 to 1 in 31 children (3.2%) aged 8 years, and the corresponding figure for the whole of the United States in 2022 was 8 and 9. In the Gulf countries, systematic review studies of the epidemiology of autism revealed a prevalence ranging from 1.4 to 29/10,000 persons. In a study in Taif, Saudi Arabia, the estimated prevalence of autism in primary school children aged 7-12 years was 0.035%. Reviews of the literature have revealed no recent prevalence statistics for children with autism/ASD in Saudi Arabia. The Saudi Ministry of Health has indicated that one in every 160 children has an ASD.

ASDs are a financial, emotional, and social burden. An autistic child's care causes more emotional burden to the parents than that of parents, compared to that of parents taking care of terminally ill children.

Social cognition is a broad term that describes cognitive processes related to perceiving, understanding, and implementing linguistic, auditory, visual, and physical cues that communicate emotional and interpersonal information. It is also defined as the perception of others, the perception of self, and interpersonal knowledge. It's the ability to understand, perceive, and interpret information about others and ourselves in a social context. It includes a wide range of processes that allow people to perceive and interpret rapidly changing social information and respond appropriately to social stimuli quickly, effortlessly, and flexibly. Also, social cognition ability gives meaning to the actions of others.

Assessment of social cognition, primarily focusing on four key domains, such as theory of mind (ToM), emotional empathy, and social perception and behavior, has been increasingly evaluated in clinical settings, given the potential implications of impairments of these skills for therapeutic decision-making. Cognitive impairment is defined as when a person has trouble remembering, learning new things, concentrating, or making decisions that affect their everyday life. The common signs of cognitive impairment may include loss of memory. Asking the same question frequently or repeating the same story over and over, unable to recognize familiar people or places, having trouble exercising judgment, such as knowing what to do in an emergency, changes in mood or behavior, difficulty in vision, difficulty planning or carrying out tasks, such as following a recipe or keeping track of monthly bills.

Studies showed that alterations in social cognition ability were associated with autism, autism severity, and autistic traits. Impairments in social cognition are often highlighted as a potential mechanism underlying social disability in autism spectrum disorder. Different social skills programs have been developed for autistic adults based on the assumption that improving social understanding and ability will improve functional outcomes.

Transcranial magnetic stimulation (TMS) is one method used to deliver electrical stimuli through the scalp in conscious humans. Generally, single-pulse TMS (including paired-pulse TMS) is used to explore brain functioning. In contrast, repetitive TMS (rTMS) is used to induce changes in brain activity that can last beyond the stimulation period. Therefore, TMS and rTMS are indirect and non-invasive methods to induce excitability changes in the motor cortex via a wire coil, generating a magnetic field that passes through the scalp. TMS Non-invasive TMS of the motor cortex leads to a twitch in the target muscle, evoking motor-evoked potential (MEP) on electromyography. As per the literature, TMS might help regulate gamma oscillations, reduce behavioral symptoms, and normalize executive and autonomic dysfunction signs. TMS is a valuable technique for assessing the underlying neurophysiology associated with several neuropathologies. It is a unique tool for establishing potential neural mechanisms responsible for disease progression. Recently, rTMS has been advanced as a potential therapeutic technique to treat selected neurologic disorders. Such neurological disorders include Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis.

Moreover, worldwide, multiple studies have repeatedly demonstrated that TMS has antidepressant effects more significantly than sham treatment and that these effects are clinically meaningful. For diagnostic uses, TMS is a potential diagnostic tool in movement disorders. TMS is used worldwide and represents a novel technique with both diagnostic and therapeutic potential. TMS is used to study cortical excitability and intracortical inhibition and investigate cortical and cortico-spinal plasticity mechanisms implicated in ASD pathophysiology. Published studies showing promising results concluded that specific rTMS protocols targeting particular regions of the cortex might lead to improvement in specific behavioral deficits in some individuals with ASD; both the investigative and therapeutic results have been mixed. rTMS and other electrical stimulation devices can modulate the brain's functioning in either a facilitatory or suppressive manner and, when applied over several sessions, can have an additive effect lasting several months. If theories are correct that cortical mechanisms of excitability, connectivity, and plasticity are abnormal in ASD, then rTMS can modulate these mechanisms. Overall, in the hands of trained technicians, rTMS might have great potential as both a diagnostic and therapeutic tool for ASD.

02

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • ASD, Autism Spectrum Disorder
  • Repetitive Transcranial Magnetic Stimulation , rTMS
  • Cognitive function
  • Social cognition
  • autistic behaviors
  • social interaction
  • sensory problems
  • excitation to inhibition imbalance
  • glutamate excitotoxicity
03

In context

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

This study's planned enrollment of 80 is above the median of 52 across 1,374 interventional studies indexed under Autism Spectrum Disorder.

Browse Autism Spectrum Disorder studies →

Lead sponsor

King Saud University is the lead sponsor of 169 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Target population:

  • Autistic individuals
  • previously Diagnosed with ASD using the American Psychiatric Association's criteria
  • previously Diagnosed using the Autism Diagnostic Observation Schedule (ADOS).

Inclusion criteria

Inclusion Criteria:

  • Male and female ASD individuals
  • age between 5 and 11 years old
  • diagnosed with ASD on prior clinical assessment using the American Psychiatric Association's DSM-V criteria and corroborated by assessment using the Autism Diagnostic Observation Schedule (ADOS).
  • Normal hearing ability based on past hearing screens.
  • Participation will be limited to higher functioning (intelligence quotient [IQ] >70) to maximize successful completion of tested paradigms, maintain alertness/attention, furthermore, the ability to follow instructions.

Exclusion criteria

Exclusion Criteria:

  • Individuals that are known to have epilepsy ( including Hx. of febrile convulsion) or have a family history of epilepsy.
  • Any individual with a previous Hx. Of head injuries
  • Any individual has been diagnosed with psychiatric illness, including ADHD, depression, psychosis, bipolar disorder, anxiety disorders, or OCD.
  • Individuals using a combination of Psychotropic Medications known for their significant seizure threshold lowering potential, for example, and not as a limitation: Bupropion, Citalopram, Duloxetine, Fluoxetine, Fluvoxamine, Mirtazapine, Paroxetine, Sertraline, Venlafaxine, Tricyclics, Olanzapine, Quetiapine, Aripiprazole, Ziprasidone, and Risperidone.
  • The presence of metallic objects, e.g., cranium clips or implanted biomedical devices.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    active rTMS group

    Male and female ASD individuals aged between 5 and 11 years old who have been diagnosed with ASD. They should have a confirmed clinical diagnosis according to the DSM-5. This will be verified by a diagnostic report or direct communication with the diagnosing clinician. Also, with normal hearing based on past hearing screens. Exclusion criteria to ensure participant safety for the rTMS intervention and included: (1) a history of seizures or epileptiform activity; (2) the presence of any metallic implants within the cranium; (3) a history of significant head trauma or loss of consciousness; and (4) the presence of implanted electronic medical devices (e.g., pacemakers, cochlear implants). All participants in both study groups did not stop their medical or behavioral therapy for ASD. However, participants will be instructed to have a consistent medication regimen or behavioral treatment for at least one month before enrollment and throughout the trial.

    Device: Stimulation with low frequency rTMS at 1 Hz

  • No intervention
    wait-list-control group

    Male and female ASD individuals aged between 5 and 11 years old who have been diagnosed with ASD. They should have a confirmed clinical diagnosis according to the DSM-5. This will be verified by a diagnostic report or direct communication with the diagnosing clinician. Also, with normal hearing based on past hearing screens. Exclusion criteria to ensure participant safety for the rTMS intervention and included: (1) a history of seizures or epileptiform activity; (2) the presence of any metallic implants within the cranium; (3) a history of significant head trauma or loss of consciousness; and (4) the presence of implanted electronic medical devices (e.g., pacemakers, cochlear implants). All participants in both study groups did not stop their medical or behavioral therapy for ASD. However, participants will be instructed to have a consistent medication regimen or behavioral treatment for at least one month before enrollment and throughout the trial.

Interventions

  • DeviceStimulation with low frequency rTMS at 1 Hz

    Stimulation with low-frequency rTMS at 1 Hz with 90% MT will be applied with a total of 180 pulses each time, which contains 18 trains with ten pulses and an interval of 20 s between any two adjacent trains. The TMS treatment course will be administered twice per week for 9 weeks; the first six treatments will be over the left DLPFC, the second six sessions will be over the right DLPFC, and the remaining six sessions will be placed on the bilateral DLPFC stimulation.

    Also known as: NeuroStar TMS Therapy System (Neuronetics, Inc; Malvern, Pennsylvania). with figure of 8- Coil and a special sensory guard ( SenStarTreatment Link).

06

What researchers measure

Primary outcomes

  1. Cognitive function

    Measure the cognitive function by using Cambridge Neuropsychological Test Automated Battery (CANTAB) spatial working memory task, looking of any Statistical significance changes in this score of cognitive testing by using CANTAB battery in the active rTMS group before and after completion of rTMs sessions and in comparison, with the control group.

    Time frame: of intervention and 2 week, 3 Months after the last session in intervention for each participant

  2. Severity level of Autism Spectrum disorders (ASD)

    Any Statistical significance change in the severity level of Autism (ASD) , looking for any changes in the score of Childhood Autism Rating Scale,Second Edition (CARS2-ST) in the active rTMS group before and after completion of rTMs sessions and in comparison, with the control group. Score will be represented as Total row score and will be interpreted based on the following : for the age between 2-12 years old * (15-29.5) Minimal to no symptoms of autism spectrum disorder * (30 - 36.5) Mild to moderate symptoms of autism spectrum disorder * ( 37 and higher) Severe symptoms of autism spectrum disorder. CARS2-ST Score minimum= 15 and maximum= - , high CARS scores mean a worse outcome.

    Time frame: pre-intervention and 2 week then 3 Months after the last session in intervention for each participant

  3. Autism Spectrum disorder (ASD) Severity level

    Any Statistical significance change in the severity level of Autism (ASD) , looking for any changes in the score of The Social Responsiveness Scale (SRS) teste in the active rTMS group before and after completion of rTMs sessions and in comparison, with the control group. Score will be represented as Total T-score and will be interpreted based on the following: * T-score of 59T or less ; the result in the normal range. * T-score of 60T through 75T; the result in the mild to moderate range. * T-score of 76T or higher; The result in the severe range. high SRS T-scores mean a worse outcome.

    Time frame: pre-intervention and 2 week then 3 Months after the last session in intervention for each participant

  4. Blood Biomarker ( Microtubule associated proteins (MAPs) ).

    Any Statistical significance change in the plasma levels of Blood biomarkers in the active rTMS group before and after completion of rTMs sessions and in comparison, with the control group. Score will be represented as plasma concentration , Units of Measure: concentration unit pg/ml

    Time frame: pre-intervention and 2 week then 3 Months after the last session in intervention for each participant

  5. Blood Biomarker ( Neuron Specific Enolase (NSE);MYO 16 (myosin XVI); kirre like nephrin family adhesion molecule 3 (KIRREL3) ).

    Any Statistical significance change in the plasma levels of Blood biomarkers in the active rTMS group before and after completion of rTMs sessions and in comparison, with the control group. Score will be represented as plasma concentration , Units of Measure: concentration unit ng/ml

    Time frame: pre-intervention and 2 week then 3 Months after the last session in intervention for each participant

  6. Blood Biomarker (glutamate transporter; EAAT2; GABA; GABRA5)

    Any Statistical significance change in the plasma levels of Blood biomarkers in the active rTMS group before and after completion of rTMs sessions and in comparison, with the control group. Score will be represented as plasma concentration , Units of Measure: concentration unit ng/ml

    Time frame: pre-intervention and 2 week then 3 Months after the last session in intervention for each participant

Secondary outcomes

  1. Psychology and behaviours

    Any change in Psychology and behaviours in participants , looking for significant statistical analysis in the score of The Child Behavior Checklist (CBCL) in the active rTMS group before and after completion of rTMs sessions and in comparison, with the control group. The CBCL uses a normative sample to create standard scores+ Percentile scores. These compare the raw score to what would be typical compared to responses for participants of the same gender and similar age . The standard scores are scaled so that 50 is average for the participants age and gender, with a standard deviation of 10 points. Higher scores indicate greater problems.

    Time frame: pre-intervention and 2 week then 3 Months after the last session in intervention for each participant

  2. Language,Speech and Communication skills

    Any speech and communication skills change in participants , looking for significant statistical analysis in the score of Orion's Pragmatic Language skills in the active rTMS group before and after completion of rTMs sessions and in comparison, with the control group. Score will be represented as Total row score for each test Item in scale higher scores mean worse outcome.

    Time frame: pre-intervention and 2 week then 3 Months after the last session in intervention for each participant

  3. Sensory Processing using Sensory Processing Measure (SPM)

    Any change in participants Sensory Processing , looking for significant statistical analysis in the score of Sensory Processing Measure (SPM)- (Home Form); in the active rTMS group before and after completion of rTMs sessions and in comparison, with the control group. Score will be represented as Total row score for scale higher scores mean worse outcome. Scores for each scale fall into one of three interpretive ranges: Typical, Some Problems, or Definite Dysfunction

    Time frame: Before the beginning of intervention and 2 week, 3 Months after the last session in intervention for each participant

  4. Sensory Processing

    Any change in participants Sensory Processing , looking for significant statistical analysis in the score of the Short Sensory Profile in the active rTMS group before and after completion of rTMs sessions and in comparison, with the control group. Score will be represented as Total row score for scale higher scores mean a better outcome; Total row score will be interpreted based on the following : (38-141) Define difference (142-154) Probable difference (155-190) typical performance

    Time frame: Before the beginning of intervention and 2 week, 3 Months after the last session in intervention for each participant

07

Study locations

1 of 1 sites recruiting
  • Department of Physiology, Autism Research and Treatment Center (ARTC), King Saud University Medical City (KSUMC)/Collage of Medicine, King Saud University
    Riyadh, Riyadh Region 12372, Saudi Arabia
    Recruiting
    • HAYFA A ALGHABBAN, MD,MSc,PhD · Contactghabbana@yahoo.com · 00966557409749
    • Laila Y AL-Ayadhi, MD,PhD · Contactlyayadhi@ksu.edu.sa
    • Hayfa A Alghabban, MD,MSc · Principal investigator
    • Laila Y AL-Ayadhi, MD,PhD · Sub investigator
08

References and documents

Publications

  • Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005 Apr;6(4):312-24. doi: 10.1038/nrn1648. PubMed 15803162 ↗
  • Baruth JM, Casanova MF, El-Baz A, Horrell T, Mathai G, Sears L, Sokhadze E. Low-Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) Modulates Evoked-Gamma Frequency Oscillations in Autism Spectrum Disorder (ASD). J Neurother. 2010 Jul 1;14(3):179-194. doi: 10.1080/10874208.2010.501500. PubMed 21116441 ↗
  • Oberman LM, Rotenberg A, Pascual-Leone A. Use of transcranial magnetic stimulation in autism spectrum disorders. J Autism Dev Disord. 2015 Feb;45(2):524-36. doi: 10.1007/s10803-013-1960-2. PubMed 24127165 ↗
  • Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World Psychiatry. 2013 Jun;12(2):92-8. doi: 10.1002/wps.20050. PubMed 23737408 ↗
  • Kaat AJ, Gadow KD, Lecavalier L. Psychiatric symptom impairment in children with autism spectrum disorders. J Abnorm Child Psychol. 2013 Aug;41(6):959-69. doi: 10.1007/s10802-013-9739-7. PubMed 23605958 ↗
  • Fakhoury M. Autistic spectrum disorders: A review of clinical features, theories and diagnosis. Int J Dev Neurosci. 2015 Jun;43:70-7. doi: 10.1016/j.ijdevneu.2015.04.003. Epub 2015 Apr 8. PubMed 25862937 ↗
  • Battle DE. Diagnostic and Statistical Manual of Mental Disorders (DSM). Codas. 2013;25(2):191-2. doi: 10.1590/s2317-17822013000200017. No abstract available. PubMed 24413388 ↗
  • Blumberg SJ, Bramlett MD, Kogan MD, Schieve LA, Jones JR, Lu MC. Changes in prevalence of parent-reported autism spectrum disorder in school-aged U.S. children: 2007 to 2011-2012. Natl Health Stat Report. 2013 Mar 20;(65):1-11, 1 p following 11. PubMed 24988818 ↗
  • Charman T, Pickles A, Chandler S, Wing L, Bryson S, Simonoff E, Loucas T, Baird G. Commentary: Effects of diagnostic thresholds and research vs service and administrative diagnosis on autism prevalence. Int J Epidemiol. 2009 Oct;38(5):1234-8; author reply 1243-4. doi: 10.1093/ije/dyp256. Epub 2009 Sep 7. No abstract available. PubMed 19737794 ↗
  • Samsam M, Ahangari R, Naser SA. Pathophysiology of autism spectrum disorders: revisiting gastrointestinal involvement and immune imbalance. World J Gastroenterol. 2014 Aug 7;20(29):9942-51. doi: 10.3748/wjg.v20.i29.9942. PubMed 25110424 ↗
  • Amr M, Bu Ali W, Hablas H, Raddad D, El-Mehesh F, El-Gilany AH, Al-Shamy H. Sociodemographic factors in Arab children with Autism Spectrum Disorders. Pan Afr Med J. 2012;13:65. Epub 2012 Nov 26. PubMed 23346279 ↗
  • Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ. 2014 Mar 28;63(2):1-21. PubMed 24670961 ↗
  • Christensen DL, Baio J, Van Naarden Braun K, Bilder D, Charles J, Constantino JN, Daniels J, Durkin MS, Fitzgerald RT, Kurzius-Spencer M, Lee LC, Pettygrove S, Robinson C, Schulz E, Wells C, Wingate MS, Zahorodny W, Yeargin-Allsopp M; Centers for Disease Control and Prevention (CDC). Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years--Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. MMWR Surveill Summ. 2016 Apr 1;65(3):1-23. doi: 10.15585/mmwr.ss6503a1. PubMed 27031587 ↗
  • Salhia HO, Al-Nasser LA, Taher LS, Al-Khathaami AM, El-Metwally AA. Systemic review of the epidemiology of autism in Arab Gulf countries. Neurosciences (Riyadh). 2014 Oct;19(4):291-6. PubMed 25274588 ↗
  • Inglese MD, Elder JH. Caring for children with autism spectrum disorder. Part I: prevalence, etiology, and core features. J Pediatr Nurs. 2009 Feb;24(1):41-8. doi: 10.1016/j.pedn.2007.12.006. Epub 2008 Jun 13. PubMed 19159834 ↗
  • Friedman S, Samuelian JC, Lancrenon S, Even C, Chiarelli P. Three-dimensional structure of the Hospital Anxiety and Depression Scale in a large French primary care population suffering from major depression. Psychiatry Res. 2001 Nov 30;104(3):247-57. doi: 10.1016/s0165-1781(01)00309-2. PubMed 11728614 ↗
  • Beer JS, Ochsner KN. Social cognition: a multi level analysis. Brain Res. 2006 Mar 24;1079(1):98-105. doi: 10.1016/j.brainres.2006.01.002. Epub 2006 Feb 28. PubMed 16513097 ↗
  • Klomjai W, Katz R, Lackmy-Vallee A. Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS). Ann Phys Rehabil Med. 2015 Sep;58(4):208-213. doi: 10.1016/j.rehab.2015.05.005. Epub 2015 Aug 28. PubMed 26319963 ↗
  • Casanova MF, Sokhadze EM, Casanova EL, Opris I, Abujadi C, Marcolin MA, Li X. Translational Neuroscience in Autism: From Neuropathology to Transcranial Magnetic Stimulation Therapies. Psychiatr Clin North Am. 2020 Jun;43(2):229-248. doi: 10.1016/j.psc.2020.02.004. Epub 2020 Apr 8. PubMed 32439019 ↗
  • Al-Ghabban H, Bashiri FA, Alenezi S, El-Ansary A, Sabr A, Alayadhi L. Therapeutic potential of low-frequency transcranial magnetic stimulation in children with autism spectrum disorder: sensory and behavioral outcomes-a randomized trial. Front Psychiatry. 2026 Mar 20;17:1725598. doi: 10.3389/fpsyt.2026.1725598. eCollection 2026. PubMed 41938847 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Apr 2028, 45 months after the start.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 45 months is above that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Apr 2025 → Apr 2028 and completion Sep 2025 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2024
First posted
Jul 29, 2024
StartActual
Jul 20, 2024
Primary completionEst.
Apr 30, 2028was Apr 2025
CompletionEst.
Sep 30, 2028was Sep 2025
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Recruiting
changed Nov 17, 2026
Sites
Department of Physiology, Autism Research and Treatment Center (ARTC), King Saud University Medical City (KSUMC)/Collage of Medicine, King Saud University is now Recruiting
Nov 17, 2026
Primary completion
Apr 30, 2025→Apr 30, 2028
Nov 17, 2026
Study completion
Sep 30, 2025→Sep 30, 2028
Nov 17, 2026
Enrollment
35 (actual)→80 (estimated)
Nov 17, 2026
Primary outcomes
1 added
What changed in the outcomes
  • AddedBlood Biomarker (glutamate transporter; EAAT2; GABA; GABRA5)Time frame: pre-intervention and 2 week then 3 Months after the last session in intervention for each participant
Nov 17, 2026
Contact
Study contact now listed: added g•••@yahoo.com · •••9749; added l•••@ksu.edu.sa. See the current contact
Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Department of Physiology, Autism Research and Treatment Center (ARTC), King Saud University Medical City (KSUMC)/Collage of Medicine, King Saud University · Riyadh, Saudi ArabiaContact added g•••@yahoo.com · •••9749Contact added l•••@ksu.edu.saContact added (no phone or email listed)Contact added (no phone or email listed)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Completed→Recruiting
    Department of Physiology, Autism Research and Treatment Center (ARTC), King Saud University Medical City (KSUMC)/Collage of Medicine, King Saud University is now Recruiting
    Primary completion Apr 30, 2025→Apr 30, 2028
    Study completion Sep 30, 2025→Sep 30, 2028
    Enrollment 35 (actual)→80 (estimated)
    Primary outcomes 1 added
    What changed in the outcomes
    • AddedBlood Biomarker (glutamate transporter; EAAT2; GABA; GABRA5)Time frame: pre-intervention and 2 week then 3 Months after the last session in intervention for each participant
    Contact Study contact now listed: added g•••@yahoo.com · •••9749; added l•••@ksu.edu.sa. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Department of Physiology, Autism Research and Treatment Center (ARTC), King Saud University Medical City (KSUMC)/Collage of Medicine, King Saud University · Riyadh, Saudi ArabiaContact added g•••@yahoo.com · •••9749Contact added l•••@ksu.edu.saContact added (no phone or email listed)Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06524310
Responsible party
Hayfa Ali Alghabban (Principal Investigator, King Saud University) — Principal investigator
First posted
Jul 29, 2024
Start date
Jul 20, 2024
Primary completion
Apr 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

HAYFA ALGHABBAN, MD,MBBS,MSc,PhD
Contact
ghabbana@yahoo.com
00966557409749
Laila Y Al-Ayadhi, MD,PhD
Contact
lyayadhi@ksu.edu.sa
HAYFA A ALGHABBAN, MD,MBBS,MSc,PhD
principal investigator · Department of Anatomy and Physiology, Faculty of Medicine, College of Medicine, Imam Mohammed Ibn Saud Islamic University, Riyadh, Saudi Arabia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion